REGN:NGS-Regeneron Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 418.84

Change

0.00 (0.00)%

Market Cap

USD 42.08B

Volume

0.71M

Analyst Target

USD 428.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-4.15 (-1.02%)

USD 107.38B
MRNA Moderna Inc

+0.96 (+0.89%)

USD 38.83B
ARGX argenx NV ADR

-0.08 (-0.02%)

USD 22.20B
BNTX BioNTech SE

-0.40 (-0.45%)

USD 21.93B
GMAB Genmab AS

-0.09 (-0.32%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-2.27 (-1.55%)

USD 18.47B
RPRX Royalty Pharma Plc

+0.16 (+0.58%)

USD 18.18B
BGNE BeiGene Ltd

+5.13 (+3.69%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-0.86 (-0.93%)

USD 16.06B
INCY Incyte Corporation

+0.09 (+0.17%)

USD 12.79B

ETFs Containing REGN

CURE:XETRA VanEck Genomics and Healt.. 8.47 % 0.00 %

-0.06 (1.17%)

USD 6.89M
IBBQ Invesco Nasdaq Biotechnol.. 8.19 % 0.00 %

-0.04 (1.17%)

USD 0.03B
BTEC:SW iShares Nasdaq US Biotech.. 8.17 % 0.00 %

-0.02 (1.17%)

USD 0.46B
PJP Invesco Dynamic Pharmaceu.. 5.75 % 0.56 %

-0.05 (1.17%)

USD 0.26B
FPX First Trust US Equity Opp.. 5.42 % 0.59 %

-0.14 (1.17%)

USD 0.70B
PBE Invesco Dynamic Biotechno.. 5.03 % 0.57 %

-0.27 (1.17%)

USD 0.23B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.99 % 0.00 %

-0.22 (1.17%)

USD 3.51M
HHL-U:CA Harvest Healthcare Leader.. 4.99 % 0.00 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 4.99 % 1.15 %

+0.01 (+1.17%)

CAD 0.33B
HHL-B:CA Harvest Healthcare Leader.. 4.99 % 0.00 %

N/A

N/A
SPQH:XETRA Global X S&P 500® Quarte.. 4.95 % 0.00 %

-0.01 (1.17%)

USD 1.89M
ZWHC:CA BMO Covered Call Health C.. 4.93 % 0.00 %

-0.02 (1.17%)

CAD 0.01B
EMEH:SW BNP Paribas Easy Energy &.. 4.68 % 0.00 %

N/A

USD 0.05B
GSCE:SW BNP Paribas Easy Energy &.. 4.68 % 0.00 %

+0.07 (+1.17%)

USD 0.25B
GSCU:SW BNP Paribas Easy Energy &.. 4.68 % 0.00 %

+0.15 (+1.17%)

USD 0.10B
UBIO 4.54 % 0.95 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.46 % 0.00 %

-0.24 (1.17%)

USD 3.51M
EGUSAS:SW UBS (Irl) Fund Solutions .. 4.35 % 0.00 %

N/A

USD 0.09B
XDNA:CA iShares Genomics Immunolo.. 4.15 % 0.00 %

+0.27 (+1.17%)

CAD 4.63M
HEAL:CA 3.97 % 0.00 %

N/A

N/A
AGNG Global X Aging Population.. 3.38 % 0.00 %

-0.19 (1.17%)

USD 0.06B
CGGR Capital Group Growth ETF 2.46 % 0.00 %

-0.06 (1.17%)

USD 5.05B
FLXU:SW Franklin U.S. Equity UCIT.. 1.11 % 0.00 %

+0.42 (+1.17%)

USD 0.17B
ACWV 0.00 % 0.20 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

+0.18 (+1.17%)

USD 0.45B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.21 (1.17%)

USD 0.10B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.15 (+1.17%)

USD 3.90M
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-0.26 (1.17%)

USD 7.79B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.30 (+1.17%)

USD 0.19B
PXLG 0.00 % 0.39 %

N/A

N/A
PVAL Putnam Focused Large Cap .. 0.00 % 0.29 %

+0.05 (+1.17%)

USD 0.31B
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

-0.10 (1.17%)

USD 0.14B
HERS-B:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (1.17%)

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (1.17%)

USD 0.49B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.06 (1.17%)

USD 8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (1.17%)

USD 0.49B
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

+0.12 (+1.17%)

CAD 0.17B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

N/A

CAD 0.01B
ZBIO 0.00 % 0.95 %

N/A

N/A
HERS:CA 0.00 % 0.62 %

N/A

N/A
FPX:LSE First Trust Global Funds .. 0.00 % 0.00 %

+12.00 (+1.17%)

USD 6.91M
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

-2.26 (1.17%)

USD 0.40M
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
EMEH:PA BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.05 (+1.17%)

USD 0.05B
FPXU:PA First Trust US Equity Opp.. 0.00 % 0.00 %

+0.02 (+1.17%)

USD 6.58M
GSCU:PA BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.05 (+1.17%)

USD 0.10B
SMRT:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.03B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

-0.03 (1.17%)

USD 0.52B
EMEH:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.10 (+1.17%)

N/A
GSDE:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.13 (+1.17%)

USD 0.26B
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

-1.20 (1.17%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (1.17%)

USD 0.52B
EMEH:XETRA BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.04 (+1.17%)

USD 0.11B
GSDE:XETRA BNP Paribas Easy Energy &.. 0.00 % 0.00 %

+0.07 (+1.17%)

USD 0.47B
SM8T:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

-0.80 (1.17%)

USD 0.04B
BIOT 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A
LYFE 0.00 % 0.00 %

N/A

N/A
SMRU:PA Amundi Index Solutions - .. 0.00 % 0.00 %

-2.42 (1.17%)

USD 3.29M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.14% 46% F 66% D+
Dividend Return N/A N/A N/A N/A F
Total Return 12.14% 46% F 66% D+
Trailing 12 Months  
Capital Gain 12.73% 80% B- 83% B
Dividend Return N/A N/A N/A N/A F
Total Return 12.73% 80% B- 82% B
Trailing 5 Years  
Capital Gain 43.44% 77% C+ 66% D+
Dividend Return N/A N/A N/A N/A F
Total Return 43.44% 76% C+ 62% D
Average Annual (5 Year Horizon)  
Capital Gain 5.42% 53% F 49% F
Dividend Return 5.42% 52% F 45% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 31.35% 68% D+ 40% F
Risk Adjusted Return 17.27% 56% F 39% F
Market Capitalization 42.08B 99% N/A 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.10 4% 17%
Price/Book Ratio 6.31 21% 16%
Price / Cash Flow Ratio 5.93 5% 14%
Price/Free Cash Flow Ratio 27.76 5% 17%
Management Effectiveness  
Return on Equity 25.90% 91% 87%
Return on Invested Capital 33.93% 94% 93%
Return on Assets 18.49% 97% 96%
Debt to Equity Ratio 10.25% 57% 77%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.